Immunology Partnerships Belharra's photoaffinity based chemoproteomics platform illuminates binding pockets across the proteome, enabling discovery of novel small molecules for immunological diseases. The ongoing Sanofi collaboration validates demand from top tier pharma and creates opportunities for co development or licensing deals with additional immunology targets.

Capacity for Collaborations Strong funding and a growing team position Belharra to undertake multi target discovery programs and partner led initiatives. The company can offer early target identification, rapid chemistry workflows, and scalable chemoproteomics enabled discovery to pharma and biotech partners.

Breakthrough Platform The platform can identify drug candidates for any binding site on any protein, in any conformational state, and in any cell type, expanding the addressable target space beyond traditional drug discovery and enabling cross disease collaboration potential.

Leadership and Talent Recent appointment of Sean Buchanan as Chief Scientific Officer strengthens scientific leadership and signals a roadmap to accelerate partner driven programs. Founders from Scripps Research and Broad Institute bolster credibility and ongoing innovation.

Geographic Advantage Headquartered in San Diego with a Bay Area presence positions Belharra in proximity to major biopharma networks, talent pools, and potential co development hubs, facilitating faster deal origination and collaboration.